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Conclusion: Post-intervention pull-back PG is a good alternative parameter for
angioplasty in CVS in dialysis patients, particular in cases of which RS was not
accordance to the criteria of successful intervention or not accurately defined.
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Background: Currently, no data support nitinol stent implantation as an alternative
treatment for long lesions in the superficial femoral artery (SFA). STELLA was a
prospective trial designed to evaluate the safety and the efficacy of primary stenting
for TASC C and D lesions in the SFA.
Methods: From November 2008 to October 2009, patients with TASC C and D de
novo SFA lesions were treated with the same endovascular technique that included
primary nitinol self-expanding stent (LifeStent, Bard Peripheral Vascular, USA)
implantation. The patients were included in a prospective single-center registry, and
were followed at 1, 3, 6, 9, 12 and 18 months. The primary endpoint was the primary
sustained clinical improvement at 12 months.
Results: Fifty-eight patients (62 limbs) were enrolled in the study (42 men; mean age:
71 years). Patients suffered from claudication (40.3%) and from critical limb ischemia
(59.7%). Lesions were TASC C (62.9%) and TASC D (37.1%). The mean length of
the treated segments was 236 mm ± 99 mm. The mean number of stents per treated
limb was 2.2. The mean hospital length of stay was 3 days (range 0 to 16 days). The
mean follow-up was 17 months, with one patient lost to follow-up. At 1 year post-
procedure, the primary endpoint of primary clinical improvement was 68.6% while
secondary sustained clinical improvement was 82.6%. Freedom from target lesion and
target vessel revascularisation were 81.1% and 96.3%. Primary and secondary
patencies were 66% and 80.9%. The ankle brachial pressure index increased from 0.58
to 0.94 (p= 0.001) and the incidence of in-stent restenosis was 19.3%.
Conclusion: Primary stenting for TASC C and D lesions in the SFA appears to be a
safe technique with acceptable clinical outcomes at 1 year. These data support the use
of endovascular repair for TASC C and D lesions in the SFA.
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Background: Popliteal Artery Aneurysms (PA) are traditionally treated surgically.
Endovascular procedures with implantation of stent grafts or covered stents have been
proposed as an alternative to surgery. Results are encouraging but some problems
remain. We developed a new concept of stent, the Multilayer Stent (MS) to treat
aneurysms and try to avoid some drawbacks encountered with endografts
Methods: This M.S is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest tests in vitro tests (theorical simulation,
computerized Fluid dynamics, Molecular Modelization) and in vivo tests demonstrate
that this MS reduces the velocity in the aneurismal sac up to 90% by modifying the
hemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the flow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MS preserves the
collateral branches allowing the possibility to cover any artery without compromising
the flow (renal, digestive arteries, supra aortic vessels…)
Results: 4 PA were treated with the MS (male: 4, mean age: 65 y.) 6 stents (Ø6 to 8
mm, length 40 to 120 mm) were implanted by percutaneous ipsilateral femoral
approach through 8F sheath. Technical success in all patients. All aneurysm
thrombosed. Mid-term follow up will be presented
Conclusion: A new concept of stent, the MS is developed to treat aneurysm. It opens
a new approach to treat peripheral aneurysms avoiding most of the complications
encountered with current endovascular techniques. The results obtained seem
promising. A larger study is ongoing
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Background: Atherectomy is sometimes used during revascularization of peripheral
arterial disease (PAD), but its impact on outcomes warrants further investigation.
Methods: We reviewed records of patients with PAD revascularized from January
2000 to December 2007 and follow-up through March 2011. Revascularized patients
who received atherectomy, thrombectomy or endarterectomy were included in the
atherectomy group, which was compared to the routine revascularization group.
Primary end point was a composite of target vessel revascularization (TVR),
amputation or death from any cause.
Results: Of 415 cases (300 patients), 74 cases (53 patients) made up the atherectomy
group. Revascularization was by percutaneous intervention with stents in 318 cases
and surgical bypass in 97 cases. Event-free survival was better in the routine
revascularization group; log rank p=0.03 (Figure). Irrespective of the method of
revascularization, there was a higher incidence of combined TVR, amputation or death
in the atherectomy group, mainly driven by TVR (Table).
Conclusion: Patients treated with atherectomy for severe peripheral arterial disease
experience a higher incidence of combined TVR, amputation or death.
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